CagriSema Stack – Cagrilintide + Semaglutide

Description

CagriSema Stack pairs Cagrilintide (amylin analogue) with Semaglutide (GLP-1 agonist) at a fixed 1:1 ratio for paired-pathway investigation.

Mechanism: GLP-1 receptor activation drives glucose-dependent insulin release and central satiety; amylin receptor activation delivers complementary gastric-emptying delay and post-prandial glucagon suppression through a non-overlapping receptor family.

Research findings: The REDEFINE phase 2/3 trial cohort reported mean weight loss of 22.7% at 68 weeks – among the highest published for any peptide combination. The pairing is a benchmark in dual-receptor metabolic research.

Handling: Lyophilized peptide. Store sealed at -20°C for long-term stability or 2-8°C short-term. Reconstitute with bacteriostatic water or 0.6% acetic acid as appropriate to the molecule.

For research purposes only. Not for human consumption. This material is intended exclusively for in-vitro laboratory and preclinical research applications conducted by qualified personnel.